The EV delivery scheme has been applied in many studies; for example, Kim et al. delivered the EV super repressor inhibitor of NF-κ B (Exo-srIkB) to mice through a novel optogenetic engineering EVs technology, reducing macrophage activation and improving I/R-AKI by lowering NF-kB signaling transduction [212]. The gene discussed is NFKB1; the disease is acute kidney injury.